The Bull Rankings scorecard — our quality-growth score is 68.5 / 100, built from three pillars scored 0–100: Quality 74, Growth 82, Value 53 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 2% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Concentra’s $34.47 price tag bets on far less growth than the business is delivering. The market is pricing a ‑2% / yr free‑cash‑flow trajectory (in year one, recovering toward 3% a year by year ten)—far slower than the 14% FY‑over‑FY revenue expansion the company just recorded. That mismatch tilts the risk‑reward toward the upside if growth holds, with heavy leverage as the main risk.
Our model gives CON a 68.5/100 quality‑growth score—the Growth pillar (82) is the engine, while the Value pillar (53) sits in the middle of its peers. The strongest pillar (Growth) tells us the business can keep adding top‑line, and the weakest (Value) says the price is only middling. With a PE of 22.2, the stock isn’t obviously cheap, and the reverse‑DCF shows the price assumes free cash flow shrinks next year even as revenue grows 14%—a pessimistic read of a growing business.
What the business actually is
Concentra runs three distinct segments: Occupational Health centers, Onsite health clinics, and an Other bucket. The core product is employer‑sponsored occupational health—workers‑comp claims, injury treatment, and preventive services delivered at dedicated centers. The Onsite clinics extend that model into the workplace, offering primary care, mobile health visits, and episodic specialty testing right where employees clock in. Ancillary lines—Concentra Telemed, a telemedicine platform for work‑related injuries, Concentra Pharmacy for repackaged meds, and Concentra Medical Compliance Administration as a TPA—feed the same employer base, deepening relationships and locking in recurring revenue.
Why it can (or can't) keep compounding
Our model’s Durable high returns signal means returns on capital have stayed high for years, and today’s ROE of 41.7% and profit margin of 8.7% fit that picture. The moat is operational: employers lock in multi‑year contracts for onsite clinics, and the telemedicine platform reduces the cost of treating injuries, making Concentra the cheaper, more convenient option versus traditional urgent‑care or external providers. Replicating that network of on‑site sites and integrated pharmacy logistics would require years of relationship building and regulatory clearance—nothing a newcomer can spin up overnight.
The valuation question
At $34.47, CON trades at a PE of 22.2—roughly in line with the sector but still above the 52‑week low of $18.55. The reverse‑DCF tells us the market is assuming ‑2% / yr FCF growth (in year one, recovering toward 3% a year by year ten), which is well below the 14% revenue growth we just saw. In other words, the price already embeds a pessimistic cash‑flow outlook despite the strong top‑line momentum. If the company can sustain its current growth, the implied valuation is too low, suggesting upside; meanwhile, the Value pillar (53) says the price is only middling against peers. The consensus 1‑year target of $39.88 reflects a modest premium, but that still assumes the growth premium will hold.
The bear case
The biggest red flag is the debt‑to‑equity ratio of 4.23. Heavy leverage magnifies any slowdown in revenue, and a modest dip below the 14% growth rate would strain cash flow enough to force asset sales or dilutive financing. Coupled with a Value pillar of 53, the market is already skeptical about pricing. If the reverse‑DCF implied growth of ‑2% materializes—meaning free cash flow actually contracts—the stock could slide toward its 52‑week low. The signal to watch is a widening spread between operating cash flow and free cash flow; a sustained negative swing would confirm the bear thesis.
What would change our mind
First, a debt‑to‑equity drop below 2.0 would signal a healthier balance sheet and give the growth engine room to breathe, lifting the Quality pillar. Second, if the profit margin climbs above 10% while maintaining the 14% revenue growth, the durable high‑returns signal strengthens, justifying a higher growth premium. Third, a PE contraction toward 15—driven by a clear earnings beat and a forward‑looking earnings guidance that exceeds consensus—would make the stock cheaper against its earnings and strengthen the value case. Until one of those thresholds materializes, the price reflects pessimism that the growth numbers don’t support, with leverage as the catch.